Company Profile
Bayer AG Stock Price, News & Catalysts
- Ticker:
- BAYRY
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
12.73 USD (-5.70%)
Close
Last updated: October 1, 2026
—
Market cap
Why the stock is moving
As of Oct 1, 2026, BAYRY closed down 5.70% at $12.73. No new same-company headline was identified in the current news window.
Company overview
Diversified Life Science Group
Bayer is a global life science company operating across agriculture, prescription medicines, and consumer health. Its portfolio combines established commercial franchises with research platforms spanning crop genetics, small molecules, biologics, radiology, cell and gene therapy, and precision oncology.
Crop Science
The Crop Science division supplies seeds, traits, crop-protection products, and digital agricultural solutions. Its major businesses include corn and soybean seed and traits, herbicides, fungicides, insecticides, vegetable and cotton seeds, and biological and data-enabled technologies intended to improve farm productivity and resilience.
Pharmaceuticals
Bayer's prescription medicines business focuses on oncology, cardiovascular and kidney disease, ophthalmology, women's health, hematology, and radiology. Key products include Nubeqa for prostate cancer, Kerendia for cardiorenal disease, Eylea for retinal disorders, Xarelto for thromboembolic disease, the Mirena contraceptive family, and contrast media and injection systems used in medical imaging.
Late-Stage Development Portfolio
The late-stage pipeline includes asundexian for secondary prevention of ischemic stroke, finerenone for non-diabetic chronic kidney disease, darolutamide regimens for additional prostate-cancer settings, and iodine-124 evuzamitide for the diagnosis of cardiac amyloidosis. Bayer is also advancing sevabertinib in HER2-mutated non-small cell lung cancer and gadoquatrane as a lower-gadolinium MRI contrast agent.
Emerging Therapeutic Platforms
Bayer is building additional pipelines through AskBio's gene-therapy platform and Vividion Therapeutics' chemoproteomics technology. AskBio programs address areas including Parkinson's disease, heart failure, and late-onset Pompe disease, while Vividion develops small molecules against traditionally difficult targets, including the WRN inhibitor VVD-214 in biomarker-defined cancers.
Consumer Health and External Innovation
The Consumer Health division markets nonprescription products across digestive health, dermatology, nutritional supplements, allergy, pain, and cold care. Bayer complements its internal research through acquisitions and partnerships, including the acquisition of Perfuse Therapeutics and its Phase 2 PER-001 ophthalmology program, as well as collaborations applying artificial intelligence to small-molecule discovery.
Future catalysts
- Regulatory decisions for asundexian in the secondary prevention of ischemic stroke following accepted applications in the United States, European Union, Japan, and China.
- FDA decision on the supplemental application for Kerendia in chronic kidney disease associated with type 1 diabetes following Priority Review designation.
- Regulatory decisions for sevabertinib in first-line HER2-mutated advanced or metastatic NSCLC in the United States and China, and in previously treated disease in Japan.
- China regulatory decision for aflibercept 8 mg in macular edema following retinal vein occlusion.
- European Union and China regulatory decisions for gadoquatrane as an MRI contrast agent.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bayer AG (BAYRY)?
Bayer AG (BAYRY) most recently closed at 12.73 USD, a -5.70% move versus the previous session.
What does Bayer AG do?
Diversified Life Science Group Bayer is a global life science company operating across agriculture, prescription medicines, and consumer health. Its portfolio combines established commercial franchises with research platforms spanning crop genetics, small molecules, biologics, radiology, cell and gene therapy, and precision oncology. Crop Science The Crop...
On which exchange is BAYRY stock listed?
Bayer AG (BAYRY) is associated with NASDAQ, United States, Biotechnology.
What is VVD-214?
AskBio programs address areas including Parkinson's disease, heart failure, and late-onset Pompe disease, while Vividion develops small molecules against traditionally difficult targets, including the WRN inhibitor VVD-214 in biomarker-defined cancers.
Which conditions is Bayer AG targeting with VVD-214?
Bayer AG is associated with oncology, cancer therapeutics, cardiovascular disease based on its company overview and current catalyst commentary.
How does Bayer AG describe recent progress with VVD-214?
Regulatory decisions for asundexian in the secondary prevention of ischemic stroke following accepted applications in the United States, European Union, Japan, and China. FDA decision on the supplemental application for Kerendia in chronic kidney disease associated with type 1 diabetes following Priority Review designation. Regulatory decisions for...
What is PER-001?
Bayer complements its internal research through acquisitions and partnerships, including the acquisition of Perfuse Therapeutics and its Phase 2 PER-001 ophthalmology program, as well as collaborations applying artificial intelligence to small-molecule discovery.
What should investors watch for with PER-001?
Regulatory decisions for asundexian in the secondary prevention of ischemic stroke following accepted applications in the United States, European Union, Japan, and China. FDA decision on the supplemental application for Kerendia in chronic kidney disease associated with type 1 diabetes following Priority Review...